Evolution and revolution in prostate cancer: what does the future hold?

Learning objective:         

After watching this broadcast, participants should be able to:

• Apply the latest expert insights, evidence, and guidelines across the full clinical spectrum of mHSPC
• Debate the role of targeted treatment of and patient identification in mCRPC
• Discuss the identification of patient populations in LPC/LAPC who might benefit from new treatment approaches

Faculty:

• Elena Castro (Spain)
• Steven Joniau (Belgium)
• Nicolas Mottet (France)
• Boris Hadaschik (Germany)

We are pleased to announce that our courses have been independently evaluated for Continuing Professional Development purposes by The CPD Certification Service. This means our courses comply with universally accepted principles of Continual Professional Development (CPD) and have been structured to meet the criteria of personal development plans.